Industry news

Drama and diagnosis on soap opera set troubles cancer doctors, puts Incyte in hot seat

Beth Snyder Bulik / FiercePharmaMarketing

Soap operas often include medical mysteries and miracles, but a couple of real-life doctors are concerned about Incyte's connection to the latest drama on General Hospital.

Pharma Must Embrace Its Social Media Role

Dawn Lacallade / Pharmaceutical Executive

Social media permeates virtually every aspect of a person’s digital life. Patients are using social media as a major source of information and an integral part of their healthcare research journey. It is therefore imperative that pharma companies be present on social media to provide full and balanced information to consumers.

Health Executives See Tech Firms Like Alphabet Remaking Industry

bSonali Basak and Ed Hammond / Bloomberg

Health-care executives expect counterparts at tech companies like Alphabet Inc., Google’s parent company, to transform their industry over three to five years, according to a Lazard Ltd. survey.

The top 15 generic drugmakers by 2016 revenue

Eric Sagonowsky / FiercePharma

Branded drugmakers weren't the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing.

Behind the numbers: The pharmaceutical industry and global health

Cristina Arnés / European Pharmaceutical Review

The most indisputable of all facts on global health is that we’re living longer and healthier lives than ever, and in an era of continuous health improvement. What were once considered life-threatening diseases are now manageable conditions, and not just for patients, but for our health systems also.

EMA Finds Patient Involvement Beneficial

BioPharm International

The European Medicines Agency (EMA) released a report on its pilot project to involve patients in the benefit-risk assessment of medicines at Committee for Medicinal Products for Human Use (CHMP) meetings. The agency concluded that patient involvement was beneficial and should continue.

17 May 2017

Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Melanoma

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced results from the melanoma cohort of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA^® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago, Illinois.

New FDA Commissioner Gottlieb Reorganizing Inspection Staff

Anna Edney / Bloomberg

Federal inspectors who ensure the safety of the nation’s food and medical products will begin specializing in certain areas, as new Food and Drug Administration commissioner Scott Gottlieb enters his first full week at the agency.

16 May 2017

Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported that the ENCORE 601 non-small cell lung cancer (NSCLC) cohort enrolling patients with disease progression on or after PD-1 therapy (programmed death receptor-1 (PD-1) and/or programmed death ligand 1, (PD-L1)) has met the pre-specified objective response threshold to advance into the second stage of the Phase 2 trial, and will re-open enrollment immediately.

Pharma and biotech rebound in annual trust study, but there's still room for improvement

Beth Snyder Bulik / FiercePharmaMarketing

When it comes to pharma, consumers still have trust issues. But the good news from Edelman’s 2017 Trust Barometer study is that things are improving. Fifty-one percent of Americans now say they trust the industry, a gain of 4% year over year. Biotech saw an even bigger jump of 12% to 62% this year. Both industries had dipped by 2% in the U.S. the year prior.